March 16 (Reuters) – Drug developer Vitae Pharmaceuticals Inc said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial.
The post Vitae Pharma’s psoriasis drug succeeds in mid-stage study appeared first on NASDAQ.